← 返回前沿论文

何时应怀疑 EB 病毒相关淋巴增殖性疾病中存在先天性免疫缺陷

英文原题:When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders.

查看英文原题

When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders.

PubMed 2022/10/06(内容时间) Clin Microbiol Infect Q1 · IF 8.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

对于 EBV 相关淋巴增殖性疾病,建议进行 IEIs 的早期筛查,因为不同形式的 IEIs 具有特定的预后和治疗意义。

研究思路结论见上方概要

超过95%的人类感染过EBV并产生抗EBV IgG抗体,从而获得免疫力。然而,在特定人群中,EBV可能诱导一系列B细胞淋巴增殖性疾病(LPDs)。EBV也可能促进T细胞和自然杀伤(NK)细胞淋巴增殖。免疫系统对于预防感染和癌症发生至关重要。先天性免疫错误(IEIs)是一组异质性超过450种遗传性疾病,易导致严重和/或反复感染、自身免疫、自身炎症或早发/严重肿瘤或淋巴增殖。T细胞和B细胞信号传导的单基因疾病是经典的IEIs,易导致EBV相关LPDs。

我们旨在概述EBV相关LPDs的各种临床表现及与这些表现相关的潜在IEIs,并讨论针对这些疾病的推荐管理和治疗选择。来源:我们于2021年9月30日检索了PubMed、Embase和Web of Science核心合集。通过检索策略和原始文献的交叉引用,识别出临床研究、系统综述、叙述性综述和病例报告。内容:有效的T细胞和NK细胞对EBV感染B细胞的细胞毒性依赖于完整的MAGT1依赖性NKG2D通路和信号淋巴细胞激活分子相关蛋白依赖性信号淋巴细胞激活分子受体。CD27与CD70之间的相互作用对于驱动EBV特异性T细胞的扩增也至关重要。由T细胞和B细胞信号缺陷和/或T细胞和NK细胞细胞毒性受损引起的IEIs易导致EBV相关淋巴增殖。这包括经典疾病,如X连锁淋巴增殖性疾病1(由SH2D1A突变引起)、X连锁淋巴增殖性疾病2(XIAP),以及其他遗传性疾病,如ITK、MAGT1、CD27、CD70、CTPS1、RASGRP1和CORO1A缺陷。EBV驱动的淋巴增殖在MST1/STK4、DOCK8、STIM1、CORO1A、IL21R、PIK3CD功能获得性突变和PI3KR1缺陷中可能表现程度较轻。

展开英文摘要原文

More than 95% of humans have been infected with Epstein-Barr virus (EBV) and develop anti-EBV IgG antibodies, conferring immunity. However, among specific populations, EBV may induce a range of B-cell lymphoproliferative disorders (LPDs). EBV may also contribute to T-cell and natural killer (NK)-cell lymphoproliferation. The immune system is essential to prevent infection and development of cancer. Inborn errors of immunity (IEIs) are a heterogenous group of more than 450 genetic disorders predisposing to severe and/or recurrent infection, autoimmunity, autoinflammation, or early-onset/severe neoplasia or lymphoproliferation. Monogenic disorders of T-cell and B-cell signalling are classic IEIs that predispose to EBV-associated LPDs.

We aimed to outline the various clinical manifestations of EBV-associated LPDs and the underlying IEIs associated with such presentations and discuss the recommended management and therapeutic options pertaining to these disorders. SOURCES: We searched PubMed, Embase, and Web of Science Core Collection on 30 September 2021. Clinical studies, systematic reviews, narrative reviews, and case reports were identified through search strategy and cross reference from primary literature. CONTENT: Effective T-cell and NK-cell cytotoxicity towards EBV-infected B cells relies on intact MAGT1-dependent NKG2D pathways and signalling lymphocyte activation molecular-associated protein-dependent signalling lymphocyte activation molecular receptors. The interaction between CD27 and CD70 is also critical to drive the expansion of EBV-specific T cells. IEIs due to T-cell and B-cell signalling defects and/or impaired T-cell and NK-cell cytotoxicity predispose to EBV-related lymphoproliferation. This includes classic disorders such as X-linked lymphoproliferative disease 1 (due to SH2D1A mutations), X-linked lymphoproliferative disease 2 (XIAP), and other genetic diseases, such as ITK, MAGT1, CD27, CD70, CTPS1, RASGRP1, and CORO1A deficiencies. EBV-driven lymphoproliferation may manifest to a lesser degree in MST1/STK4, DOCK8, STIM1, CORO1A, IL21R, PIK3CD gain-of-function, and PI3KR1 deficiencies. IMPLICATIONS: Early screening for IEIs is indicated in cases of EBV-related lymphoproliferation because different forms of IEIs have specific prognostic and therapeutic implications.

论文信息

作者
Sacco KA、Notarangelo LD、Delmonte OM
第一作者单位
Laboratory of Clinical Immunology and Microbiology, Immune Deficiency Genetics Section, National Institutes of Health, Bethesda, MD, USA.United States
通讯作者单位
Laboratory of Clinical Immunology and Microbiology, Immune Deficiency Genetics Section, National Institutes of Health, Bethesda, MD, USA. Electronic address: ottavia.delmonte@nih.gov.United States
文献类型
综述
期刊
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2023 Apr
原文标识
PubMed 36209991 · DOI 10.1016/j.cmi.2022.10.003